Fig. 2: Analysis of PBRM1 and EZH2 interactions in Silico. | npj Precision Oncology

Fig. 2: Analysis of PBRM1 and EZH2 interactions in Silico.

From: Prolonged survival in a patient with pbrm1 mutated metastatic cholangiocarcinoma receiving tazemetostat

Fig. 2: Analysis of PBRM1 and EZH2 interactions in Silico.

Bar graph showing the mutation frequency of PBRM1 in human pan-cancer (A). Scheme of PBRM1 where all mutations (green for missense, black for truncating, brown for inframe, orange for splice, and purple for fusion) are displayed. The height represents the number of cases (B). Bar graph illustrating the percentage of mutations in PBRM1 alone or combination with EZH1 (i) or EZH2 (ii) in cholangiocarcinoma tumors (C). The dot plot shows the gene expression correlation between PBRM1 and EZH1 in cholangiocarcinoma tumors (D). Box and whiskers graph indicating the sensitivity of ccRCC cell lines to GSK343 (EZH2 inhibitor) depending on PBRM1 WT (grey dots) or mutated (red dots). (E).

Back to article page